Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant HAPLN1
- Development stage
- Preclinical
- Lead developer
- Johns Hopkins Bloomberg School of Public Health
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intradermal
01
Overview
Recombinant HAPLN1 (rHAPLN1) is a recombinant form of the Hyaluronan and Proteoglycan Link Protein 1, a secreted extracellular matrix (ECM) protein. HAPLN1 is essential for maintaining the structural integrity of the ECM by stabilizing the binding of hyaluronan to chondroitin sulfate proteoglycans. Research, particularly in the context of aging and oncology, has demonstrated that age-dependent loss of HAPLN1 in the dermis leads to increased matrix stiffness. This physical change in the tumor microenvironment triggers the upregulation of endothelial ICAM1 and the downregulation of VE-cadherin, which erodes vascular integrity and promotes melanoma metastasis. Preclinical studies have shown that intradermal treatment with rHAPLN1 can restore vascular barrier function and reduce the metastatic potential of melanoma cells by normalizing the aged ECM.
- Other names
- recombinant Hyaluronan and Proteoglycan Link Protein 1
02
Targets
Hyalectans (Lectican family proteoglycans)ACAN (Aggrecan core protein)
Beyond the preview
Go deeper on recombinant HAPLN1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant HAPLN1.